⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PCVX News
Vaxcyte, Inc. Common Stock
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
globenewswire.com
PCVX
Form 8-K
sec.gov
PCVX
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com
PCVX
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
globenewswire.com
PCVX
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
globenewswire.com
PCVX
VERA
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
globenewswire.com
PCVX
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
globenewswire.com
PCVX
Form 8-K
sec.gov
PCVX
Form 8-K
sec.gov
PCVX
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
globenewswire.com
PCVX